Illumina Announces New Organizational Alignment -8K
Illumina (NASDAQ: ILMN) today unveiled a strategic roadmap for moving next-generation sequencing (NGS) into new markets, leveraging its technology leadership and new organizational alignment around those markets to drive growth. During an investor day where executives presented plans for this growth, Illumina also shared workflow innovations designed to simplify the sequencing experience and new market solutions derived from the company's sample to answer technology base.
“Earlier this week we announced two transformative platforms that redefine next-generation sequencing, with the addition of the NextSeq™ 500 System and the HiSeq® X Ten to our market leading portfolio. Today we previewed additional innovations that position us to seize opportunities across research and clinical markets, as well as to deliver the industry's simplest, most efficient sequencing experience to our customers,” said Jay Flatley, Illumina's Chief Executive Officer.
Illumina shared the following strategies and innovations around its core market targets.
In reproductive health, Illumina will expand its offerings based on the verifi® laboratory-developed non-invasive prenatal test (NIPT), submitting an IVD version on the HiSeq® 2500 system for FDA premarket approval by the end of 2014. It also will offer an NGS-based solution for preimplantation genetic screening, VeriSeq™ PGS, launching initially on the MiSeq® system, as well as an array-based karyomapping single gene preimplantation genetic diagnosis (PGD) solution to identify embryos with genes associated with severe genetic disorders. In oncology, the company previewed a targeted sequencing strategy that includes supporting the clinical community with content. Illumina is also working in collaboration with the oncology community to develop test guidelines and infrastructure to build actionable cancer genomics solutions.
In emerging markets, Illumina will launch a human leukocyte antigen (HLA) typing product in mid-2014 for laboratories seeking next-generation sequencing on the MiSeq® platform that will be faster, less expensive, and more accurate than current technologies. Additionally, the company introduced the MiSeq® Forensic Genomics System (MiSeq FGx), the first targeted forensic NGS system, which will simultaneously interrogate short tandem repeats and other valuable genetic markers to provide more comprehensive identification information from both challenging and standard biological samples. The complete sample to answer solution, including consumables and software, is expected to be available in the first six months of 2014.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.